[Skip to Navigation]
November 1995

Treatment of Cytomegalovirus Retinitis With Intraocular Sustained-Release Ganciclovir Implant

Author Affiliations

New York, NY

Arch Ophthalmol. 1995;113(11):1354-1355. doi:10.1001/archopht.1995.01100110014003

Dr Martin and his colleagues are to be congratulated on their important article, "Treatment of Cytomegalovirus [CMV] Retinitis With Intraocular Sustained-Release Ganciclovir Implant."1 The implant is clearly effective in delaying progression of CMV retinitis in newly diagnosed patients. The absence of smoldering retinitis is of particular interest. Earlier studies of the implant were not randomized and included previously treated and newly diagnosed patients, making it difficult to draw conclusions concerning efficacy. There is a good discussion of the two major pitfalls with the implant, development of retinitis in a previously unaffected eye and development of visceral disease. However, the rate and timing of retinal detachment is of some concern. Although the patients had peripheral retinitis, there was no description of the percentage of retinal involvement or the zones involved at baseline. The extent, location, and activity of retinitis are important factors in determining the risk for development of retinal

Add or change institution